Campus Virchow Klinikum

3 weeks ago | jamanetwork.com | Stefan Anker |Campus Virchow Klinikum |Tim Friede |Javed Butler

Visual Abstract. Efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency Figure 1.  Recruitment, Randomization, and Follow-Up in the FAIR-HF2 Trial FAIR-HF2 indicates Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity and Mortality. aThe precise reasons are unknown.